The prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study: Baseline characteristics of the population

Cerebrovascular Diseases

Volumn 27, Issue 6, 2009, Pages 608-613

  Bousser, M G ^a,i   Amarenco, P ^a   Chamorro, A ^b   Fisher, M ^c   Ford, I ^d   Fox, K ^e   Hennerici, M ^g   Mattle, H P ^h   Rothwell, P M ^f  

^a INSERM   (France)

^b HOSPITAL CLÍNIC   (Spain)

^c University of Massachusetts   (United States)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e ROYAL BROMPTON HOSPITAL   (United Kingdom)

^f JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^g UNIVERSITY OF HEIDELBERG   (Germany)

^h UNIVERSITY OF BERN   (Switzerland)

ⁱ HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Antiplatelet therapy; Aspirin; Ischemic stroke; PERFORM Study; Stroke prevention; Terutroban; TP receptor antagonist; Transient ischemic attack

Indexed keywords

ACETYLSALICYLIC ACID; TERUTROBAN;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CAUCASIAN; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; RISK FACTOR; STROKE; TRANSIENT ISCHEMIC ATTACK; VITAL SIGN;

ACTIVITIES OF DAILY LIVING; AGED; ASPIRIN; COGNITION; DIABETES COMPLICATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; INTERNATIONAL COOPERATION; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; NAPHTHALENES; PLATELET AGGREGATION INHIBITORS; PROPIONIC ACIDS; RECEPTORS, THROMBOXANE; RECURRENCE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STROKE;

EID: 65449173947     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000216835     Document Type: Article

References (24)

1. World Health Organization: The Atlas of Heart Disease and Stroke. http://www.who. int/cardiovascular-diseases/resources/at-las/en/index.html (accessed February 5,2009).
2. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, Hailpern SM, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O'Donnell C, Roger V, Sorlie P, Steinberger J, Thom T, Wilson M, Hong Y: Heart disease and stroke statistics- 2008 Update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008;117:e25-e146.
3. Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, Gorelick P, Halperin J, Harbaugh R, Johnston SC, Katzan I, Kelly-Hayes M, Kenton EJ, Marks M, Schwamm LH, Tomsick T: Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: cosponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Circulation 2006;113:e409-e449.
4. Patrono C, Coller B, Dalen JE, FitzGerald GA, Fuster V, Gent M, Hirsh J, Roth G: Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 2001;119:39S-63S.
5. Gaussem P, Reny JL, Thalamas C, Chatelain N, K rou mova M, Jude B, Boneu B, Fiessinger JN: The specific thromboxane receptor antagonist S18886:pharmacokinetic and pharmacodynamic studies. J Thromb Haemost 2005;3:1437-1445.
6. Bal C, Crassard I, Simmonneau G, Bergmann JF, Bousser MG, Drouet L: Effect of the thromboxane A2 receptor antagonist terutroban on experimental arterial thrombogenesis after repeated administration in patients treated for the prevention of ischemic stroke. Cerebrovasc Dis, in submission.
7. 2 receptor antagonist S18886 in patients with coronary artery disease treated with aspirin. J Am Coll Cardiol 2003;41:1198-1204.
8. Cayatte AJ, Du Y, Oliver-Krasinski J, Lavielle G, Verbeuren TJ, Cohen RA: The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler Thromb Vasc Biol 2000;20:1724-1728.
9. Xu S, Jiang B, Maitland KA, Bayat H, Gu J, Nadler JL, Corda S, Lavielle G, Verbeuren TJ, Zuccollo A, Cohen RA: The thromboxane receptor antagonist S18886 attenuates renal oxidant stress and proteinuria in diabetic apolipoprotein E-deficient mice. Diabetes 2006;55:110-119.
10. 2 receptor antagonist, prevents occurrence of spontaneous brain damage in stroke-prone rats via anti-inflammatory activities. Cerebrovasc Dis 2007;23(suppl 2):137.
11. Bousser MG, Amarenco P, Chamorro A, Fisher M, Ford I, Fox K, Hennerici MG, Mattle HP, Rothwell PM;PERFORM Study Investigators:Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin with Terutroban in Patients with a History of Ischemic Stroke or Transient Ischemic Attack (PERFORM) Study. Cerebrovasc Dis 2009;27:509-518.
12. Kasner SE: Clinical interpretation and use of stroke scales. Lancet Neurol 2006;5:603-612.
13. Folstein MF, Folstein SE, McHugh PR:'Minimental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
14. Isaacs B, Kennie AT: The Set test as an aid to the detection of dementia in old people. Br J Psychiatry 1973;123:467-470.
15. Zazzo R: Test des deux barrages. Actualités pédagogiques et psychologiques. Neuchâtel, Delachaux et Nestlé, 1974, vol 7.
16. Lawton MP, Brody EM: Assessment of older people:self-maintaining and instrumental activities of daily living. Gerontologist 1969;9:179-186.
17. Amarenco P, Bogousslavsky J, Callahan AS, Goldstein L, Hennerici M, Sillsen H, Welch MA, Zivin J: Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study. Cerebrovasc Dis 2003;16:389-395.
18. Amarenco P, Bogousslavsky J, Callahan A, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA: High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549-559.
19. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ: Management of atherothrombosis with clopidogrel in highrisk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): study design and baseline data. Cerebrovasc Dis 2004;17:253-261.
20. Diener HC, Sacco R, Yusuf S:Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: The Prevention Regimen for Effectively avoiding Second Strokes trial (PRoFESS). Cerebrovasc Dis 2007;23:368-380.
21. Grau AJ, Weimar C, Buggle F, Heinrich A, Goertler M, Neumaier S, Glahn J, Brandt T, Hacke W, Diener HC:Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke data bank. Stroke 2001;32:2559-2566.
22. Bogousslavsky J, Van MG, Regli F: The Lausanne Stroke Registry: analysis of 1,000 consecutive patients with first stroke. Stroke 1988;19:1083-1092.
23. Rothwell PM, Coull AJ, Giles MF, Howard SC, Silver LE, Bull LM, Gutnikov SA, Edwards P, Mant D, Sackley CM, Farmer A, Sandercock PA, Dennis MS, Warlow CP, Bamford JM, Anslow P: Change instroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet 2004;363:1925-1933.
24. Schulz UG, Rothwell PM: Differences in vascular risk factors between etiological subtypes of ischemic stroke: importance of population-based studies. Stroke 2003;34:2050-2059.